{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:18:15Z","timestamp":1792167495279,"version":"4.4.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>A deeper understanding of the immune landscape in patients with idiopathic multicentric Castleman disease (iMCD) is essential to establish early prognostic stratification and uncover novel therapeutic targets. We used single-cell RNA sequencing of peripheral blood mononuclear cells (PBMCs) from a cohort of 15 patients with iMCD and 4 healthy controls. To explore the sources of interleukin-6 (IL-6), we included lymph node and bone marrow samples for comparison with PBMCs. Our results indicate that IL-6 primarily originates from the lymph nodes, particularly from activated B cells. Similarly, in peripheral blood, activated B cells are also the main source of IL-6. IL-6 receptor is primarily expressed in monocytes in PBMCs, with CCL monocytes showing the strongest activation of the IL-6 signaling pathway. This suggests that CCL monocytes in iMCD may play an important role in driving peripheral inflammatory storms. CellChat analysis reveals that during disease flares, CCL monocytes interact with specific natural killer (NK)\/NKT cells through enhanced type II interferon (IFN-II) signaling, whereas this interaction significantly diminishes during remission, indicating a significant role for IFN-II in the pathogenesis of iMCD. Notably, serum IFN-\u03b3 levels positively correlate with both disease severity and treatment resistance, a finding validated by a large independent iMCD cohort. Our findings confirm that the IL-6 pathway remains central to iMCD pathogenesis and highlight a significant role for IFN-II pathway activation in amplifying inflammatory storms. Our findings provide valuable biomarkers for assessing disease severity and identify new therapeutic targets for iMCD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024027689","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T21:06:27Z","timestamp":1743455187000},"page":"76-88","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["IFN-\u03b3 promotes the progression of iMCD by activating inflammatory monocytes"],"prefix":"10.1182","volume":"146","author":[{"given":"Xuejiao","family":"Yin","sequence":"first","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Ding","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Ge","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbo","family":"Wang","sequence":"additional","affiliation":[{"name":"4Department of Bioinformatics, Cosmos Wisdom Biotech Co Ltd, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuopo","family":"Lv","sequence":"additional","affiliation":[{"name":"5Department of Biotechnology, College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuxia","family":"Luo","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liya","family":"Ma","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Yu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juying","family":"Wei","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiumei","family":"Yao","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4575-3287","authenticated-orcid":false,"given":"Liangshun","family":"You","sequence":"additional","affiliation":[{"name":"1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China"},{"name":"2Department of Hematology, Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou, China"},{"name":"3Department of Hematology, Zhejiang Key Laboratory for Precision Diagnosis and Treatment of Hematological Malignancies, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"16","key":"2025070311222313100_bib1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2025070311222313100_bib2","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025070311222313100_bib3","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/bloodadvances.2017009654","article-title":"Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas","volume":"2","author":"Nagy","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"2025070311222313100_bib4","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3324\/haematol.2021.280370","article-title":"The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease","volume":"108","author":"Horna","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2025070311222313100_bib5","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41379-021-00950-3","article-title":"Transcriptome and unique cytokine microenvironment of Castleman disease","volume":"35","author":"Wing","year":"2022","journal-title":"Mod Pathol"},{"issue":"1","key":"2025070311222313100_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hoc.2017.09.003","article-title":"The role of interleukin-6 in Castleman disease","volume":"32","author":"Yoshizaki","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"issue":"22","key":"2025070311222313100_bib7","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2018-05-848671","article-title":"Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease","volume":"132","author":"Fajgenbaum","year":"2018","journal-title":"Blood"},{"issue":"20","key":"2025070311222313100_bib8","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee","year":"2018","journal-title":"Blood"},{"issue":"37","key":"2025070311222313100_bib9","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1038\/s41388-024-03128-8","article-title":"scRNA-seq reveals the landscape of immune repertoire of PBMNCs in iMCD","volume":"43","author":"Yin","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"2025070311222313100_bib10","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1038\/s41467-023-42718-0","article-title":"Peripheral helper-T-cell-derived CXCL13 is a crucial pathogenic factor in idiopathic multicentric Castleman disease","volume":"14","author":"Harada","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"2025070311222313100_bib11","doi-asserted-by":"crossref","first-page":"7813","DOI":"10.3390\/ijms24097813","article-title":"T-cells subsets in Castleman disease: analysis of 28 cases including unicentric, multicentric and HHV8-related clinical forms","volume":"24","author":"Fraticelli","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"18","key":"2025070311222313100_bib12","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1182\/blood.2023021992","article-title":"Single-cell landscape of idiopathic multicentric Castleman disease in identical twins","volume":"143","author":"Chan","year":"2024","journal-title":"Blood"},{"issue":"1","key":"2025070311222313100_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nri.2017.76","article-title":"Single-cell RNA sequencing to explore immune cell heterogeneity","volume":"18","author":"Papalexi","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025070311222313100_bib14","doi-asserted-by":"crossref","first-page":"153712","DOI":"10.1016\/j.phymed.2021.153712","article-title":"Cascade of immune mechanism and consequences of inflammatory disorders","volume":"91","author":"Megha","year":"2021","journal-title":"Phytomedicine"},{"issue":"87","key":"2025070311222313100_bib15","first-page":"123","article-title":"Interferon-\u03b3 and systemic autoimmunity","volume":"16","author":"Pollard","year":"2013","journal-title":"Discov Med"},{"issue":"1","key":"2025070311222313100_bib16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12974-015-0438-x","article-title":"Amelioration of Japanese encephalitis by blockage of 4-1BB signaling is coupled to divergent enhancement of type I\/II IFN responses and Ly-6C(hi) monocyte differentiation","volume":"12","author":"Kim","year":"2015","journal-title":"J Neuroinflammation"},{"issue":"10","key":"2025070311222313100_bib17","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1172\/JCI126091","article-title":"Identifying and targeting pathogenic PI3K\/AKT\/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"2025070311222313100_bib18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025070311222313100_bib19","first-page":"100720","article-title":"A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria","volume":"34","author":"Zhang","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"issue":"4","key":"2025070311222313100_bib20","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/blood.V74.4.1360.1360","article-title":"Pathogenic significance of interleukin-6 (IL-6\/BSF-2) in Castleman's disease","volume":"74","author":"Yoshizaki","year":"1989","journal-title":"Blood"},{"issue":"4","key":"2025070311222313100_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/jpm10040269","article-title":"Pulmonary manifestations of plasma cell type idiopathic multicentric Castleman disease: a clinicopathological study in comparison with IgG4-related disease","volume":"10","author":"Nishimura","year":"2020","journal-title":"J Pers Med"},{"issue":"5","key":"2025070311222313100_bib22","first-page":"474","article-title":"Diagnostic utility of interleukin-6 expression by immunohistochemistry in differentiating Castleman disease subtypes and reactive lymphadenopathies","volume":"46","author":"Post","year":"2016","journal-title":"Ann Clin Lab Sci"},{"issue":"7","key":"2025070311222313100_bib23","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/ajh.25123","article-title":"Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease","volume":"93","author":"Pierson","year":"2018","journal-title":"Am J Hematol"},{"key":"2025070311222313100_bib24","doi-asserted-by":"crossref","first-page":"42316","DOI":"10.1038\/srep42316","article-title":"Elevated serum interferon \u03b3-induced protein 10 kDa is associated with TAFRO syndrome","volume":"7","author":"Iwaki","year":"2017","journal-title":"Sci Rep"},{"issue":"suppl 1","key":"2025070311222313100_bib25","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1182\/blood-2022-167829","article-title":"Serum proteomics identifies interferon gamma signaling in idiopathic multicentric Castleman disease [abstract]","volume":"140","author":"Mumau","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2025070311222313100_bib26","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood.2020007930","article-title":"JAK inhibition for murine HLH requires complete blockade of IFN-\u03b3 signaling and is limited by toxicity of JAK2 inhibition","volume":"138","author":"Chaturvedi","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2025070311222313100_bib27","doi-asserted-by":"crossref","first-page":"e135031","DOI":"10.1172\/jci.insight.135031","article-title":"Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease","volume":"5","author":"Pai","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"2025070311222313100_bib28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/toxsci\/kfx083","article-title":"From the cover: interplay between IFN-\u03b3 and IL-6 impacts the inflammatory response and expression of interferon-regulated genes in environmental-induced autoimmunity","volume":"158","author":"Cauvi","year":"2017","journal-title":"Toxicol Sci"},{"issue":"19","key":"2025070311222313100_bib29","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1182\/blood.2019002792","article-title":"Increased mTOR activation in idiopathic multicentric Castleman disease","volume":"135","author":"Arenas","year":"2020","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/1\/76\/2383762\/blood_bld-2024-027689-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/1\/76\/2383762\/blood_bld-2024-027689-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:22:31Z","timestamp":1751556151000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/1\/76\/536436\/IFN-promotes-the-progression-of-iMCD-by-activating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024027689","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,3]]},"published":{"date-parts":[[2025,7,3]]}}}